In this study, we investigate the immune composition of the tumour microenvironment in SBA using a subset of immunomodulatory biomarkers which include the T-cell markers (CD3, CD4, and CD8), macrophage marker (CD68), and immune checkpoint biomarkers (IDO1, ICOS, LAG3 and PD-L1) as well as their prognostic impact in terms of disease outcome and patient survival. The gene discussed is ICOS; the disease is neoplasm.